PURPOSE: This study was to elucidate the potential benefit of beta blockers on cancer survival. METHODS: We comprehensively searched PubMed, Embase, and the Cochrane Library from their inception to April 2013. Two authors independently screened and reviewed the eligibility of each study and coded the participants, treatment, and outcome characteristics. The primary outcomes were overall survival (OS) and disease-free survival (DFS). RESULTS: Twelve studies published between 1993 and 2013 were included in the final analysis. Four papers reported results from 10 independent groups, resulting in a total of 18 comparisons based on data obtained from 20,898 subjects. Effect sizes (hazard ratios, HR) were heterogeneous, and random-effects models were used in the analyses. The meta-analysis demonstrated that beta blocker use is associated with improved OS (HR 0.79; 95 % CI 0.67-0.93; p = 0.004) and DFS (HR 0.69; 95 % CI 0.53-0.91; p = 0.009). Although statistically not significant, the effect size was greater in patients with low-stage cancer or cancer treated primarily with surgery than in patients with high-stage cancer or cancer treated primarily without surgery (HR 0.60 vs. 0.78, and 0.60 vs. 0.80, respectively). Although only two study codes were analyzed, the studies using nonselective beta blockers showed that there was no overall effect on OS (HR 0.52, 95 % CI 0.09-3.04). CONCLUSION: This meta-analysis provides evidence that beta blocker use can be associated with the prolonged survival of cancer patients, especially patients with early-stage cancer treated primarily with surgery.
PURPOSE: This study was to elucidate the potential benefit of beta blockers on cancer survival. METHODS: We comprehensively searched PubMed, Embase, and the Cochrane Library from their inception to April 2013. Two authors independently screened and reviewed the eligibility of each study and coded the participants, treatment, and outcome characteristics. The primary outcomes were overall survival (OS) and disease-free survival (DFS). RESULTS: Twelve studies published between 1993 and 2013 were included in the final analysis. Four papers reported results from 10 independent groups, resulting in a total of 18 comparisons based on data obtained from 20,898 subjects. Effect sizes (hazard ratios, HR) were heterogeneous, and random-effects models were used in the analyses. The meta-analysis demonstrated that beta blocker use is associated with improved OS (HR 0.79; 95 % CI 0.67-0.93; p = 0.004) and DFS (HR 0.69; 95 % CI 0.53-0.91; p = 0.009). Although statistically not significant, the effect size was greater in patients with low-stage cancer or cancer treated primarily with surgery than in patients with high-stage cancer or cancer treated primarily without surgery (HR 0.60 vs. 0.78, and 0.60 vs. 0.80, respectively). Although only two study codes were analyzed, the studies using nonselective beta blockers showed that there was no overall effect on OS (HR 0.52, 95 % CI 0.09-3.04). CONCLUSION: This meta-analysis provides evidence that beta blocker use can be associated with the prolonged survival of cancerpatients, especially patients with early-stage cancer treated primarily with surgery.
Authors: Stanley Lemeshow; Henrik Toft Sørensen; Gary Phillips; Eric V Yang; Sussie Antonsen; Anders H Riis; Gregory B Lesinski; Rebecca Jackson; Ronald Glaser Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-09-20 Impact factor: 4.254
Authors: Amal Melhem-Bertrandt; Mariana Chavez-Macgregor; Xiudong Lei; Erika N Brown; Richard T Lee; Funda Meric-Bernstam; Anil K Sood; Suzanne D Conzen; Gabriel N Hortobagyi; Ana-Maria Gonzalez-Angulo Journal: J Clin Oncol Date: 2011-05-31 Impact factor: 44.544
Authors: Helene Hartvedt Grytli; Morten Wang Fagerland; Sophie D Fosså; Kristin Austlid Taskén; Lise Lund Håheim Journal: Prostate Date: 2012-07-20 Impact factor: 4.104
Authors: Pei Yang; Weiye Deng; Yaqian Han; Yingrui Shi; Ting Xu; Juan Shi; Hesham Elhalawani; Yu Zhao; Xiaoxue Xie; Fan Lou; Rong Zhang; Hekun Jin Journal: Am J Cancer Res Date: 2017-04-01 Impact factor: 6.166
Authors: Marisa Coelho; Cátia Soares-Silva; Daniela Brandão; Franca Marino; Marco Cosentino; Laura Ribeiro Journal: J Cancer Res Clin Oncol Date: 2016-10-05 Impact factor: 4.553
Authors: Ann M Decker; Younghun Jung; Frank C Cackowski; Kenji Yumoto; Jingchen Wang; Russel S Taichman Journal: Mol Cancer Res Date: 2017-08-16 Impact factor: 5.852
Authors: Ondřej Fiala; Pavel Ostašov; Aneta Rozsypalová; Milan Hora; Ondřej Šorejs; Jan Šustr; Barbora Bendová; Ivan Trávníček; Jan Filipovský; Jindřich Fínek; Tomáš Büchler Journal: Target Oncol Date: 2021-08-07 Impact factor: 4.493
Authors: Mark K Farrugia; Sung Jun Ma; David M Mattson; Leayn Flaherty; Elizabeth A Repasky; Anurag K Singh Journal: Am J Clin Oncol Date: 2020-12-01 Impact factor: 2.787
Authors: Julius C Heemelaar; Augustinus D G Krol; Marloes Louwerens; Saskia L M A Beeres; Eduard R Holman; Martin J Schalij; M Louisa Antoni Journal: Int J Cardiol Heart Vasc Date: 2021-06-25